183 related articles for article (PubMed ID: 38263860)
1. Truncated PD1 Engineered Gas-Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells.
Zhang S; Liang Y; Ji P; Zheng R; Lu F; Hou G; Yang G; Yuan L
Adv Sci (Weinh); 2024 Mar; 11(12):e2305891. PubMed ID: 38263860
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicle-mediated immunoregulation in cancer.
Yamamoto T; Yamamoto Y; Ochiya T
Int J Hematol; 2023 May; 117(5):640-646. PubMed ID: 35951282
[TBL] [Abstract][Full Text] [Related]
4. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
5. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
6. The importance of exosomal PDL1 in tumour immune evasion.
Daassi D; Mahoney KM; Freeman GJ
Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
8. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
10. Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy.
Xu F; Jiang D; Xu J; Dai H; Fan Q; Fei Z; Wang B; Zhang Y; Ma Q; Yang Q; Chen Y; Ogunnaike EA; Chu J; Wang C
Cell Rep; 2023 Oct; 42(10):113138. PubMed ID: 37738123
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1 signals in cancer cells.
Kornepati AVR; Vadlamudi RK; Curiel TJ
Nat Rev Cancer; 2022 Mar; 22(3):174-189. PubMed ID: 35031777
[TBL] [Abstract][Full Text] [Related]
13. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
14. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
15. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.
Zhang A; Wang S; Sun Y; Zhang Y; Zhao L; Yang Y; Zhang Y; Xu L; Lei Y; Du J; Chen H; Duan L; He M; Shi L; Liu L; Wang Q; Hu L; Zhang B
Exp Hematol Oncol; 2023 Sep; 12(1):85. PubMed ID: 37777797
[TBL] [Abstract][Full Text] [Related]
16. Optimal Irreversible Electroporation Combined with Nano-Enabled Immunomodulatory to Boost Systemic Antitumor Immunity.
Peng W; Cao Y; Zhang Y; Zhong A; Zhang C; Wei Z; Liu X; Dong S; Wu J; Xue Y; Wu M; Yao C
Adv Healthc Mater; 2024 Mar; 13(7):e2302549. PubMed ID: 38059737
[TBL] [Abstract][Full Text] [Related]
17. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
18. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
19. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
20. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
